key: cord-0849704-t6mc97z0
authors: Xu, Peng-wei; Wu, Xuan; Wang, Hong-ning; Ma, Bing-cun; Ding, Meng-die; Yang, Xin
title: Assembly and immunogenicity of baculovirus-derived infectious bronchitis virus–like particles carrying membrane, envelope and the recombinant spike proteins
date: 2015-10-13
journal: Biotechnol Lett
DOI: 10.1007/s10529-015-1973-3
sha: a59dbafccfef3ecd0d6a227b5d2162be654da5aa
doc_id: 849704
cord_uid: t6mc97z0

OBJECTIVE: To assemble infectious bronchitis virus (IBV)-like particles bearing the recombinant spike protein and investigate the humoral immune responses in chickens. RESULTS: IBV virus-like particles (VLPs) were generated through the co-infection with three recombinant baculoviruses separately encoding M, E or the recombinant S genes. The recombinant S protein was sufficiently flexible to retain the ability to self-assemble into VLPs. The size and morphology of the VLPs were similar to authentic IBV particles. In addition, the immunogenicity of IBV VLPs had been investigated. The results demonstrated that the efficiency of the newly generated VLPs was comparable to that of the inactivated M41 viruses in eliciting IBV-specific antibodies and neutralizing antibodies in chickens via subcutaneous inoculation. CONCLUSIONS: This work provides basic information for the mechanism of IBV VLP formation and develops a platform for further designing IBV VLP-based vaccines against IBV or other viruses. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s10529-015-1973-3) contains supplementary material, which is available to authorized users.

Avian infectious bronchitis virus (IBV), which belongs to gamma-coronavirus genus, contains four Peng-wei Xu and Xuan Wu have contributed equally to this work.

Electronic supplementary material The online version of this article (doi:10.1007/s10529-015-1973-3) contains supplementary material, which is available to authorized users. structural proteins: the spike (S), membrane (M), envelope (E) and nucleocapsid (N) proteins.

The S protein is post-translationally cleaved into two distinct functional subunits: an N-terminal subunit (S1) that is an immunodominant protein carrying epitopes eliciting virus-neutralizing antibodies (Gallagher and Buchmeier 2001) ; and a membraneanchored subunit (S2) that is noncovalently attached to S1 having a transmembrane domain that spans the viral membrane and anchors the S protein in the virion (Bosch et al. 2003) . Not surprisingly most new vaccine candidates against IBV are S1-targeted (Chen et al. 2010; Shil et al. 2011; Lin et al. 2012) . Both M and E proteins are critical factors in virion assembly and budding and interactions between the two seem to be the minimum requirements for coronavirus VLP (virus-like particles) formation (Vennema et al. 1996; Masters 2006; Masters et al. 2006 ). The S protein, however, is was not essential but is incorporated into VLP by interactions with the M protein when present (Ho et al. 2004; Bosch et al. 2005) .

IBV is responsible for an acute and contagious upper-respiratory tract disease in commercial chickens and is a severe economic burden on the poultry industry worldwide. Vaccination with live attenuated or inactivated vaccines is still the most effective way to control IBV. Unfortunately, current vaccines are unable to provide chickens with sufficient protection because of the limitations of traditional vaccines and multiple serotypes of epidemic IBV strains. Consequently, it is essential to find a feasible way for developing a more safe and effective vaccine strategy. Compared with either whole-virus vaccines or recombinant subunit vaccines, VLPs have some prominent advantages to become promising vaccine candidates. As they lack viral genetic material, VLPs are noninfective and thus are safe. Furthermore, VLPs are highly immunogenic due to their structure being similar to authentic viruses with highly repetitive antigenic epitopes (Kushnir et al. 2012) . Although there has been some research on coronavirus VLPs, few studies have focused on IBV. Therefore, in this work novel IBV VLPs have been constructed through the co-infection with three recombinant baculoviruses separately expressing M, E and the recombinant S protein containing the S1 subunit fused to the transmembrane domain and the cytoplasmic tail (TM/CT) of S2 subunit. Additionally, as a vaccine to inoculate specific-pathogen-free chickens, the humoral immunity was evaluated.

Sf9 insect cells were cultured in serum-free Sf-900 III SFM at 27°C. The Massachusetts 41 (M41) strain of IBV was purchased from China Institute of Veterinary Drug Control.

To obtain the recombinant S (rS) gene, S1 and TM/CT fragments of S gene were fused by means of restriction enzyme digestion and ligation ( Fig. 1) . Then, the rS, M and E genes were individually cloned into transfer vector pFastBac 1 to generate pFB-rS, pFB-M and pFB-E. The construction of these recombinant transfer vectors is shown in Supplementary Fig. 1 . Primers used are listed in Supplementary Table 1 .

The transfer vectors were separately transformed into DH10Bac E. coli cells (Invitrogen) to construct recombinant shuttle plasmids rBac-rS, rBac-M and rBac-E via site-specific transposition. Three Fig. 1 Schematic diagram for construction of the recombinant S gene. The S1 and TM/CT genes were amplified by RT-PCR with primers shown in Supplementary Table 1. The products of S1 and TM/CT genes were digested with BamHI, respectively, and then ligated together to generate the rS gene. Additionally, a linker was inserted between S1 and TM/CT to ensure their own structures and functions. ''SS'' indicates the signal peptide sequence (amino acid positions 1-16) of IBV M41 S protein.

''S1'' indicates the S1 subunit (amino acid positions 17-537) of S protein without signal peptide. ''TM/CT'' indicates the transmembrane domain and the cytoplasmic tail (amino acid positions 1092-1162) of S protein. ''Linker'' indicates the flexible peptide (-GlyGlySerSer-), among which the coding sequence for ''GlySer'' is just the recognition sequence of BamHI recombinant baculoviruses, designated rBV-rS, rBV-M and rBV-E were subsequently generated through lipofectin-mediated transfection. A plaque assay was used to purify and determine the titers of the recombinant baculoviruses. The procedures of transfection and plaque assay were performed according to the manual of baculovirus expression system (Invitrogen).

Sf9 cells were respectively infected with the recombinant baculoviruses rBV-rS, rBV-M and rBV-E at a multiplicity of infection (MOI) of 5. Expression of the recombinant proteins was detected by indirect immunofluorescence assay. Subsequently, western blot was performed to further analyze the recombinant proteins in culture supernatants and cell lysates.

For preparation of VLPs, Sf9 cells were co-infected with the three recombinant baculoviruses at an MOI of 5 for 96 h. The culture media were collected and filtered. The supernatants were ultracentrifuged at 80,0009g for 1.5 h at 4°C. After the sediments were resuspended in PBS, the solution was further purified by centrifuging at 80,0009g for 5 h at 4°C through a discontinuous sucrose gradient. Purified VLPs at the interface between 40 and 30 % (w/v) sucrose were collected.

A transmission electron microscope was used to analyze the formation of IBV VLPs. Purified VLPs were loaded onto a carbon-coated copper grid for 5 min, and then negatively-stained with 2 % (w/v) phosphotungstic acid for 1 min. The VLPs were observed under the EM. For further confirmation of Chicken-derived anti-IBV hyperimmune serum and HRPconjugated rabbit anti-chicken antibody were used to conduct western blot. Three separate bands of approximately 67, 25 and 12 kDa corresponding to the molecular weight of rS, M and E proteins were detected in the cell lysates, while only one specific band corresponding to M protein was detected in the supernatant samples, which may demonstrate that M protein could be secreted to extracellular space when expressed alone the viral proteins presented in these VLPs, Western blot was performed to analyze the VLPs samples.

Two groups of 10-day-old specific-pathogen-free (SPF) chickens (n = 20) were subcutaneously (s.c.) inoculated twice (day 0 and 14) with IBV VLPs or inactivated M41 viruses. The inoculation dose of VLPs or inactivated M41 contained 2 lg S1 proteins. 20 more SPF chickens were immunized with PBS as a negative control. Sera were collected via the jugular vein before initial immunization (day 0) and at 14 days after each immunization (day 14 and 28) for analysis.

To determine the IBV-specific antibody levels in sera (day 0, 14 and 28) with an indirect ELISA, the inactivated M41virosomes were used as coating antigen. Sera samples were diluted at 1:80 with PBS containing 5 % (v/v) skimmed milk. HRP-conjugated donkey anti-chicken antibody was used as the secondary antibody. Moreover, IBV-neutralizing antibody titers in sera (day 28) were detected by a virus neutralization test performed on chicken embryos. Sera samples were heat-inactivated at 56°C for 30 min and then two-fold serially diluted. Diluted sera were incubated with 10 2 EID50 of IBV M41 viruses at 37°C for 1 h. Subsequently, the mixture was inoculated into 9-day-old SPF chicken embryos.

The data among groups were statistically analyzed by Student's two-tailed t test. p values less than 0.05 (p \ 0.05) was considered to be statistically significant.

The results were shown in Figs. 2 and 3.

Electron microscopy of the visible VLPs was shown in Fig. 4a and the results of further analysis were shown in Fig. 4b .

The results demonstrate that the VLPs are competent to induce significant IBV-specific antibodies and neutralizing antibodies in chicken via s.c. administration. Further details are shown in Fig. 5 .

Most research concerned with the construction of coronavirus VLPs tend to support the view that the interactions between the M and E proteins are the minimum requirements for the efficient formation of VLPs (Ho et al. 2004; Hsieh et al. 2005) . While the S protein is dispensable, it can be incorporated when present. However, there are still some controversies concerning the mechanism of coronavirus VLPs Fig. 4 Characterization of IBV VLPs. a Electron microscopy analysis of VLPs. The formation of IBV VLPs from Sf9 cells coinfected with rBV-rS, rBV-M and rBV-E was examined by an electron microscope after the VLPs-included culture media were purified by ultra-centrifugation with a discontinuous sucrose density gradient. The visible VLPs were similar to authentic IBV particles in size and spherical morphology. Bar = 100 nm. b Western blot analysis of VLPs. Lane 1: purified VLPs samples. Lane 2: purified culture media from cells co-infected by rBV-M and rBV-E with the only difference that rBV-rS was absent. Lane 3: negative control samples from cells infected with wBV. Chicken-derived anti-IBV hyperimmune serum was used to detect the viral proteins. The results demonstrate that when rS and E proteins are co-expressed with M protein, all the three viral proteins can be detected in culture media by the formation of VLPs. In addition, the total protein concentration of purified VLPs samples was determined by a modified Bradford protein assay kit; and the amount of rS protein presented in the VLPs samples was estimated by densitometry of Coomassie Blue-stained SDS-PAGE gel with BSA as standard (data not shown). The percent of rS protein in the VLPs was calculated as 28.4 % (w/w) formation although it widely accepted that the existence of the major antigen is critical for the successful design of a genetic-engineered vaccine. In view of these considerations, IBV VLPs were assembled through co-infection with three recombinant baculoviruses separately encoding M, E or the recombinant S genes.

A recombinant S protein was used in current research rather than the traditional whole S protein, as a consequence of the following considerations. The S1 protein is sufficient to elicit good protective immunity against IBV (Cavanagh 2007; Lin et al. 2012) . The incorporation of coronavirus S protein into VLPs is closely related to the interactions between the TM/CT domain of S protein and the CT domain of M protein, (de Haan et al. 1999; Bosch et al. 2005) . In addition, the heterologous expression of the fulllength S protein is difficult as it is a large protein (180 kDa) with intensive hydrophobicity and is highly glycosylated. Accordingly, a recombinant S protein was constructed with a flexible peptide inserted between the two elements to keep their own structures and functions. Moreover, it would be convenient to replace the S1 subunit with other foreign epitopes or target molecules when exploiting this newly establised VLP as an universal platform.

There are two main strategies commonly used to produce VLPs composed of more than one structural proteins in insect systems: co-infection and coexpression (Sokolenko et al. 2012) . However, the former was the more accepted strategy in the current study because co-infection is flexible for further comprehensive studies on the molecular and dynamic mechanism of VLP formation. In addition, the present study demonstrated that IBV VLPs could elicit robust humoral immune responses in specific-pathogen-free chickens that were comparable to the inactivated M41 viruses. More importantly, after booster vaccination, the VLPs even induced slightly higher neutralizing antibody titers than the inactivated M41 viruses (p [ 0.05). This was mainly due to the S1 subunit that was carrying most of the neutralizing epitopes, and part of S proteins in M41, had lost their native structures during inactivation. This result further confirmed the incorporation of the modified S protein in VLPs.

In conclusion, IBV VLPs composed of rS, M and E proteins were produced in Sf9 insect cells and the Fig. 5 IBV-specific antibodies and neutralizing antibodies detected in chicken sera. a IBV-specific antibody titers in sera (day 0, 14 and 28) were analyzed by indirect ELISA. Some higher but not statistically different levels of IBV-specific antibody titers were detected both in VLPs and the inactivated M41 groups after the initial vaccination (day 14) as compared to the control group (p [ 0.05). The antibody titers of the two experimental groups increased notably after the booster vaccination (day 28) and were very significantly higher than that of the control group (p \ 0.01). In addition, the levels of antibody titers in chickens that after the booster vaccinated with VLPs and inactivated M41 viruses were significantly higher in contrast to that after the initial vaccination (p \ 0.05). Data represent the mean antibody titer ± SD for 20 chickens. b IBVneutralizing antibody titers detected in sera. After booster vaccination (day 28), the neutralizing antibody titers in each group of chickens were detected by a virus neutralization test performed on chicken embryos. IBV VLPs were competent to elicit considerable neutralizing antibodies comparable to that of the inactivated M41 viruses, and the antibody titers of the both groups were significantly higher in contrast with that of the negative control group (p \ 0.01). Neutralizing antibody titer was calculated as the reciprocal of the highest serum dilution that neutralized 50 % of 10 2 EID50 of viruses in SPF chicken embryos humoral immune responses in chicken have been investigated. The findings demonstrate that the modified S protein is sufficiently flexible to retain the ability to self-assemble into VLPs. The VLPs may serve as a promising strategy to control IBV. This work provides basic information for the mechanism of IBV VLP formation and develops a platform for further design of IBV VLP-based vaccines against IBV or other viruses.

The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex

Spike protein assembly into the coronavirion: exploring the limits of its sequence requirements

Coronavirus avian infectious bronchitis virus

Construction and immunogenicity of a recombinant fowlpox vaccine coexpressing S1 glycoprotein of infectious bronchitis virus and chicken IL-18

Mapping of the coronavirus membrane protein domains involved in interaction with the spike protein

Coronavirus spike proteins in viral entry and pathogenesis

Assembly of human severe acute respiratory syndrome coronavirus-like particles

Assembly of severe acute respiratory syndrome coronavirus RNA packaging signal into virus-like particles is nucleocapsid dependent

Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development

Avian reovirus sigma C enhances the mucosal and systemic immune responses elicited by antigen-conjugated lactic acid bacteria

The molecular biology of coronaviruses

Genetic and molecular biological analysis of protein-protein interactions in coronavirus assembly

Development and immunogenicity of recombinant GapA(?) Mycoplasma gallisepticum vaccine strain ts-11 expressing infectious bronchitis virus-S1 glycoprotein and chicken interleukin-6

Co-expression vs. co-infection using baculovirus expression vectors in insect cell culture: benefits and drawbacks

Nucleocapsid-independent assembly of coronavirus-like particles by co-expression of viral envelope protein genes